Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets

Stockholm, Sweden and Tonghua, China - July 6, 2010 - Swedish Orphan Biovitrum
(STO: SOBI) and Dongbao today announced their intent to form a strategic
Commercial Alliance.  In such an alliance, Swedish Orphan Biovitrum would be the
marketing and sales partner of choice for Dongbao's pipeline of
Biopharmaceuticals and other drugs in Europe and Dongbao would be the marketing
and sales partner of choice for Swedish Orphan Biovitrum's marketed and pipeline
products in China.

The announced Commercial Alliance would be a partnership where both parties will
benefit in two ways.  First, each party secures a marketing and sales partner
for its own products in an important new territory, China in the case of Swedish
Orphan Biovitrum and Europe in the case of Dongbao.  Second, each party gains
access to a new portfolio of exciting products for its home markets.

The parties also announced that they intend to complete the first stage of the
Commercial Alliance by completing ongoing negotiations regarding the following
products:

  * Iron Sucrose from Dongbao where Swedish Orphan Biovitrum will be the
    exclusive marketing and sales partner in Europe for this product.

  * Kineret and the late stage development project Kiobrina from Swedish Orphan
    Biovitrum where Dongbao will be the exclusive marketing and sales partner in
    China for these products.

Swedish Orphan Biovitrum intends to deepen its collaboration with Dongbao,
including its affiliate Rechon Life Science Group, as regards manufacturing
services.

An alliance will address current pharmaceutical market trends in both China and
Europe.  The Chinese pharmaceutical market is large and rapidly growing.  It is
also becoming more and more receptive to high value, innovative products that
meet significant unmet medical needs.  Thus, Swedish Orphan Biovitrum's products
are a good fit with the strong and growing high value, specialty segment of the
Chinese market.  Similarly, the Biosuperior segment of the European
pharmaceutical market is rapidly growing.  Again, this makes market entry in
Europe for Dongbao's portfolio of Biosuperiors timely and in-line with regional
trends.

Martin Nicklasson, CEO of Swedish Orphan Biovitrum stated "We are very pleased
to have identified a partner in Dongbao with a successful track record of
selling high value biotechnology products in China.  Dongbao has a deep
understanding of biotechnology products from a manufacturing and clinical
development perspective.  Moreover, they have an impressive track record of
success in regulatory affairs as well as in marketing and sales.  Thus, we see
Dongbao as the perfect partner to help Swedish Orphan Biovitrum to realize the
significant opportunity for our products in the Chinese market.

Additionally, we are excited about gaining access to Dongbao's pipeline of high
value Biosuperiors.  We look forward to working with these products over the
long term to realize the full commercial potential of these products in Europe."

Dr. Zhaoqi Li, Vice President of Dongbao Enterprise Group and the Chairman of
the Board of Rechon Life Science Group expressed that "A fast growing Chinese
market is now offering great opportunity for innovative and high value
pharmaceutical products. We admire Swedish Orphan Biovitrum's remarkable efforts
and achievements in the development of specialist pharmaceutical products for
rare diseases. We will contribute, with the best of our effort, to the
successful introduction of Swedish Orphan Biovitrum's product into the Chinese
market as well as into the emerging markets where Dongbao/Rechon already have a
strong network established.

It has been a very interesting journey made by Dongbao in the development of
high value biotech products. By combining Swedish Orphan Biovitrum's knowledge,
experience and market network with Dongbao's interesting range of biotech
products we will have a prosperous future in Europe.

Partnership has always been important for Dongbao's business success. The
establishment of a strong collaboration with Swedish Orphan Biovitrum will add
good value for our future development. We are very excited that such a
Commercial Alliance with Swedish Orphan Biovitrum will enable smooth access of
our products into the European market and, in the other direction, we are very
pleased to offer our support for the successful entry of Swedish Orphan
Biovitrum's products into the Chinese market."

About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical
company with an international market presence. The company is focused on
providing and developing specialist pharmaceuticals for rare disease patients
with high medical needs. The portfolio consists of about 60 marketed products
and an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer
supportive care and inherited metabolic disorders.

Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and
approximately 500 employees. The head office is located in Sweden and the share
(STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit
www.sobi.com.

For more information please contact: Swedish Orphan Biovitrum AB (publ):

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mailerik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on July 6, 2010 at 8:30 a.m. CET.



[HUG#1429736]